Edgewise Therapeutics (EWTX)
(Delayed Data from NSDQ)
$18.08 USD
+1.22 (7.21%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $19.53 +1.46 (8.05%) 5:40 PM ET
3-Hold of 5 3
D Value F Growth B Momentum D VGM
Cash flow Statements
Fiscal Year End for Edgewise Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -100.16 | -67.64 | -42.81 | -17.12 | NA |
Depreciation/Amortization & Depletion | -7.79 | 0.00 | 0.27 | 0.19 | NA |
Net Change from Assets/Liabilities | -1.56 | 4.09 | 4.63 | 1.95 | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Operating Activities | 17.56 | 10.92 | 4.40 | 0.35 | NA |
Net Cash From Operating Activities | -91.95 | -52.64 | -33.51 | -14.63 | NA |
Property & Equipment | -5.75 | -5.55 | -0.67 | -0.20 | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Investments | 108.63 | -65.03 | -241.56 | -24.18 | NA |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Cash from Investing Activities | 102.89 | -70.58 | -242.23 | -24.38 | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 53.33 | 129.89 | 0.36 | 120.28 | NA |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Financing Activities | -0.17 | -0.25 | 186.02 | 0.00 | NA |
Net Cash from Financing Activities | 53.17 | 129.64 | 186.38 | 120.28 | NA |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Change In Cash & Equivalents | 64.10 | 6.43 | -89.35 | 81.26 | NA |
Cash at Beginning of Period | 21.99 | 15.57 | 104.92 | 23.65 | NA |
Cash at End of Period | 86.10 | 21.99 | 15.57 | 104.92 | NA |
Diluted Net EPS | -1.57 | -1.26 | -1.14 | NA | NA |
Fiscal Year End for Edgewise Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -60.02 | -28.53 | -100.16 | -70.02 | -44.31 |
Depreciation/Amortization & Depletion | -5.64 | -2.63 | -7.79 | -6.15 | -4.27 |
Net Change from Assets/Liabilities | 0.87 | -2.32 | -1.56 | -1.36 | -2.33 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 10.10 | 4.87 | 17.56 | 12.41 | 7.85 |
Net Cash From Operating Activities | -54.70 | -28.60 | -91.95 | -65.12 | -43.06 |
Property & Equipment | -0.52 | -0.30 | -5.75 | -5.58 | -5.13 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -230.42 | -268.01 | 108.63 | 81.49 | 57.61 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -230.94 | -268.31 | 102.89 | 75.90 | 52.48 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 243.07 | 241.07 | 53.33 | 0.39 | 0.39 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.05 | 0.00 | -0.17 | -0.21 | 0.00 |
Net Cash from Financing Activities | 243.03 | 241.07 | 53.17 | 0.18 | 0.39 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -42.61 | -55.83 | 64.10 | 10.96 | 9.81 |
Cash at Beginning of Period | 86.10 | 86.10 | 21.99 | 21.99 | 21.99 |
Cash at End of Period | 43.49 | 30.26 | 86.10 | 32.96 | 31.81 |
Diluted Net EPS | -0.34 | -0.33 | -0.46 | -0.41 | -0.34 |